Opio is a technology company.
Opio has raised $300K across 1 funding round.
Opio has raised $300K in total across 1 funding round.
Opio Connect is a healthcare technology company founded in 2019 that develops robotic automation systems for opioid treatment programs (OTPs), primarily addressing the opioid crisis through efficient methadone dose preparation.[1][3][4] Its flagship product, ZING (also referred to as Bodhi in some contexts), is a robotic machine that automates measuring, bottling, capping, sealing, labeling, and photographing up to 28 doses of liquid methadone in just 4 minutes—4x faster than manual processes—helping OTPs combat nursing and pharmacist shortages while expanding patient access amid the fentanyl epidemic.[1][3][4] The company serves OTPs and satellite clinics across North America, solving labor-intensive tasks that divert staff from patient care, with $2.75M raised to date and positive customer feedback on efficiency and compliance.[1][4]
Opio Connect targets the rapidly growing opioid use disorder (OUD) treatment market, projected to double from $3.1B in 2023 to over $6B by 2030, by enabling remote service delivery, improving retention, and ensuring equitable access to methadone—the most effective treatment for fentanyl addiction.[3][4]
Opio Connect was co-founded in 2019 by Lanea George (née Norbeck), a nurse and board-certified clinical pharmacist with expertise in OUD care and healthcare technology, and Mike Pokorny, an engineer who designed patented niche electric motors.[1][3] The idea emerged from George's hospital experience with manual methadone dosing amid nursing shortages; in 2019, she and Pokorny brainstormed automation using off-the-shelf parts for pouring, sealing, labeling, and capping liquid methadone.[1] Norbeck quit her job in 2020, and they officially launched Opio Connect in January 2021, quickly developing ZING, which leverages robotics to handle compliance-heavy tasks in OTPs.[1][3]
Early traction included filing 4 patents in drug rehabilitation, health informatics, and infrared technology, securing $2.75M in funding (last round $900K about a year ago), and gaining adoption in OTPs for its speed and reliability.[1][3][4]
(Note: A separate, smaller AI consultancy named Opio Inc. exists in Los Angeles but lacks connection to this healthcare-focused entity and minimal public details.[2])
Opio Connect rides the opioid crisis wave, where fentanyl drives OUD as the fastest-growing U.S. healthcare sector and #1 killer of ages 18-45, demanding scalable methadone delivery amid provider shortages.[3][4] Timing aligns with post-2023 market doubling to $6B+ by 2030 and tech's push into healthcare automation, filling gaps left by outdated OTP systems reliant on manual labor.[1][3] Favorable forces include regulatory emphasis on OUD access, nursing crises, and robotics adoption in compliance-heavy fields; it influences the ecosystem by enabling OTP expansion, remote care (e.g., correctional facilities), and data-driven quality like ATLAS integration from co-founders' prior work.[1][3][4]
Opio Connect is poised for acceleration with recent funding, patent portfolio, and ZING's validated efficiency in real OTPs, potentially capturing share in the exploding OUD market.[1][4] Next steps likely include scaling deployments, AI-enhanced features for predictive dosing, and partnerships for nationwide satellite networks amid persistent fentanyl threats.[3][4] Evolving trends like workforce automation mandates and telehealth integration will amplify its influence, transforming OTPs from bottlenecked clinics to high-capacity care hubs—ultimately saving lives by making methadone as accessible as the crisis demands.[1][3]
Opio has raised $300K in total across 1 funding round.
Opio's investors include AUC Angels.
Opio has raised $300K across 1 funding round. Most recently, it raised $300K Seed in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $300K Seed | AUC Angels |